Jroon I used to sell Carlson product (and I personally took the Elite EPA Gems), and they are a good product. 1,000 mg per cap but not cheap.

Thanks Kiwi. Interesting. There has been some dilution last year. Appears they have enough cash for the next 2 or 3 years. I will have to dive a little deeper as it appears even if the drug is successful it will be a few years before gaining profitability. I am assuming they might be a BO target at some point but they already have a market cap of 2b.

North, by public service I am wondering or assuming that you mean it wouldn't have to be paid for by Amarin? Otherwise, Amarin does not want to spend ad money whilst the Generics have a strangle hold on US sales.

Totally agree Ernie. Only time it would work is if the company is earning gobs of money. Those with losses - the losses just get magnified with RS

Excellent post FFS. To piggyback onto your post and to explain pleiotropic effects to anyone interested here is a good paper:

https://www.tandfonline.com/doi/pdf/10.1080/00325481.2021.1921491

It would be nice to not only have the stock price rise next week but also to get some positive piece of fundamental news. I guess we aren’t expecting such so it will have to be a surprise, which is good because it may have more impact that way.

Obviously feel better at the end of the day the way it closed.

My son says he told me about ASTS a while back (when it was in the single digits) but like a nut I never jumped on it. Could have been because I had no loose cash at that moment, or maybe I was looking at something else. Congrats on your success with it. Another missed opportunity for me.

Kind of looks overbought. I guess launch of satellites coming up. Seems analysts’ price targets are below current stock price.

Guess they would need shareholder and UK regulatory approval for that second $50 mil purchase? Hopefully the pps doesn’t stay here that long, and probably wouldn’t after that first 50 mil purchase.

A FUDster about RS yes. Not spreading such about Amarin.

Our cash position and having a great drug approved by FDA, the EU, and many other places in the world are clear and positives for the company. Unfortunity revenue is decreasing - sales in EU not yet matching losses in the US. Market is forward looking (but not enough forward) so they see decelerating earnings and a slow but sure degradation of the cash position. No question the loss of CVS Caremark caused them to put the brakes on the BB.

Speaking of CVS Caremark. It is one thing for them to cover GV and put brand V on a higher tier, but to remove V entirely from the formulary is outrageous. The only drug in that category (omegas) that is approved for CVD reduction and they don’t even have it on their formulary. I guess they are not covering scripts for CVD with IPE. Yeah right. Absolutely criminal. Best healthcare system money can buy.

Well let’s hope but a little more transparency about Priceline. They were not in danger of delisting by the time the RS went into effect. And, to be fair, the success story didn’t really materialize until five years after the RS. RS is bad, period.

“Yet Priceline had already started to recover even before the reverse split took place. Between February and June of 2003, Priceline shares more than tripled, and the travel company certainly didn't need to worry about delisting fears by the time it actually moved forward with the reverse split in June.”

https://www.fool.com/investing/2016/08/23/priceline-reverse-split-the-biggest-stock-comeback.aspx

Excellent piece. Thanks for posting Sleven.

“Although currently restricted to use in those patients with hypertriglyceridaemia on statins, it is clear that the beneficial effects of IPE are not only limited to this population.”

I picked up shares today at the open. Seems undervalued considering script growth, although I understand the risks going forward.

Thanks for your input. I am thinking that there are not many examples where Sarissa owned such a low priced stock in order to glean how they would handle this. Also I am wondering if the ultimate goal is the sale of Amarin to another company, does that really require being listed on the Nasdaq?

“unequivocally”.

Don’t disagree with any of the catalysts you mention, but outside of Italy reimbursement, I worry that none of the others will occur before delisting. The only way I see a RS as a positive is only in those situations where a company is very profitable (not just by a penny or two), so that would be a concern here.

No question that that is a big concern. The longer we sit under a buck the more nervous I get about such an eventuality. On top of that like you mention, the next couple of quarters look dire on the earnings front. No question that the loss of CVS Caremark was the reason for the BB never being initiated. Question is what is there in the near future that could possibly stir a rise in the pps enough to get it over a buck?

Was reading that in Q2, institutions were net buyers of the stock. But, according to this, company insiders did nothing but sell the stock the last couple of years. Not familiar with this site but here it is:

https://www.insiderdashboard.com/search?page=1&query=ARDX

Careful. You what they say about figures.

One 30% was of a larger number than the 2nd 30%. But nonetheless, your main thrust is correct and hopefully not all is lost with our investment here.

Kiwi, on the Yahoo board, I read where some mentioned that in the last CC ARDX mentioned that they were waiting for govt lawyers to be assigned to the case after which ARDX's lawyers could have some conversations with the opposing side. Some on that board speculated that if no resolution occurs during those talks, that the judge may even order a stay (something about people's lives and quality of life being at stake). So wonder if any of those are a possibility.

Kiwi, considering most would say that the most recent earnings report was very good or even excellent, why has the pps not reacted?

Is it all related to Congressional action and the lawsuit against CMS? Market must be thinking that scripts for X will not match expectations.

Raggy, CRMD did pretty good too today.

Dar, happened to wake up this morning and as usual lay there thinking about all kinds of things. But this morning my mind wandered to the contrast in situations from just after R-I results came out to the current status with Amarin. Looking at that comparison it is so hard to fathom how we could have gone from a situation with so much promise to such despair.

Having sold vitamins and supplements for a good portion of my latter business life, I worked within the confines of making sure we did not diagnose, prescribe, or medicate or make any illegal claims. Although a number companies who flew undetected would to do just that. But many of them got caught by the FDA or FTC and were slapped with cease and desist letters followed by fines if they persisted. BUT here we have in the WIDE OPEN, clearly for everyone to see, companies selling a patented product for an indication for which their drug has NOT been approved. But nothing is done. What is the point of FDA approval?

PG and those directors have no shame so doubtful Selce’s letter spurs them to do anything, so I guess Selce has to rely on Iljin calling for an emergency meeting.

Just beat it like it owes you money.

Monstrous volume. Sometimes that is a low, so at this price might hold remaining shares

Yes. I worded my post poorly. I meant to query whether upon successful study results but before formal approval for CRC indication, there might be a rush to prescribe. And of course primarily in the UK and EU, as it doesn’t appear that Amarin can shake loose of the Generics here in the US.

Keep it up. 12 years - great news. I wonder since there are a number of V users (mostly for CVD) on it for a number of years, whether their data can be plumbed to glean whether V helps with prevention?

Kiwi, like you suggest, we have to wait till the results in 2026. However, since Vazkepa is already approved for CVD in GB and the EU, and although I assume it would need to submit for approval of label expansion, do you think that docs and clinics would be quite willing to go ahead and push V significantly before label expansion for post operative CRC?

Do you have any thoughts/concerns that it did not fare well with the primary endpoint? "A phase 2 randomised trial of preoperative EPA free fatty acid 2 g daily in patients undergoing surgery for CRC liver metastasis showed no difference in the primary endpoint (histological tumour proliferation index) compared with placebo."

Not really sure how "histological tumor proliferation index" ties in with (or has anything implication for) DFS. Apparently not much of a connection since as you pointed out EPA at 2 gms daily significantly improved DFS.

After the discussion here a week or two ago concerning PBMs, and showing how convoluted our healthcare insurance system is, I was stunned to find out today that another company with which we have had no direct knowledge of lost some of our personal data (guess I am naive or unaware). I mean we go to doctors' offices, we have Medicare and Fed BCBS health insurance, and pickup drugs at a couple of different pharmacies - mostly Walgreens.

In today's mail my wife got a letter from a company called "Change Healthcare". They claim that our data may have been stolen. They had a breach back in February but only today (Aug 12) did we receive notification of such. Apparently they are a payment processor and patient data information processor that is a subsidiary of UNH. I guess that BCBS must contract with them (or maybe the providers do?) to process claims or payments. What they did not mention in the notification letter received today is that they apparently paid a ransom of $22 million to get the data back. How do we know that the thieves didn't copy that data before returning it? Change Healthcare must wonder too as they are offering free credit monitoring and advising us to check all our accounts. All the crap we have to do to make up for other peoples' failings. I wonder how many other entities we don't know about are upstairs screwing with our data? What a system.

Thanks Capt.

I believe this is the study and it gives just a bit more info:

https://pubmed.ncbi.nlm.nih.gov/38030258/

Thanks for posting Sleven. So they are shooting for a total of 448 patients with 300 all ready set up by this past May.

Wish they had given more detail about the protocol. How much IPE per day and what the placebo is. Notice both donated by Amarin.

Thanks North for the NLST article. Good read. Disappointing to hear that after 14 years and despite court victories - no monetary recompense has happened. I guess that is why a number of us here have little hope that legal maneuvers here in the US will amount to much. John Thero - dropped the ball and did not do his fiduciary duty.

Not sure if you didn’t word it correctly, but pharmacy do not provide insurance - insurance companies do.

A few months old, but an article about how PBMs are driving community pharmacies out of business:

https://prospect.org/health/2024-03-21-pbm-insurer-mafia-community-pharmacies/

Thanks Sleven. Now I remember what I wanted to add. And this shows my confusion.

As BCBS's description of what CVS Caremark does for them, namely; "provides covered services to our members", and knowing that CVS Caremark provides those services to many different insurance carriers, AND using my prior explanation that CVS Caremark enforces or implements these various insurance companies' rules, I cannot understand how that mesh with this statement that CVS Caremark for its commercial plans as of July 1 will stop the filling of scripts with brand V. It sounds like that kind of directive would override any insurance company that still wanted to cover brand V.

But we have all seen statements from CVS and Amarin stating that that is what is happening as of July 1. So although the PBM provides services that the insurance company covers, it may seemingly have some power to override or impose their decision on the formulary. It seems we are dealing with so many players that disregard patent protections and are willingly infringing.

You are correct, that when numbers are small, percentages can look huge.

Sleven, DAR, I know that I am confused by our convoluted health insurance system so I hope that this post is not as confusing, but it probably will be. Hopefully you will be able to understand what I am trying to say.

For many, many years now I have had Federal BCBS health insurance through my wife. And, for as long as I can remember CVS Caremark as been the PBM for FEP BCBS. Here is how they describe it: "Preferred retail pharmacy means a pharmacy has an agreement with CVS Caremark to provide covered services to our members. You can choose from more than 55,000 network pharmacies nationwide when filling your prescriptions."

Up until (now I can't remember if it was Jan 2023 or 2022) I always got brand V and my BCBS covered it and I was able to use the Amarin coupon and brought the cost to me down to as low as $9 at times. I could be wrong but as of Jan (2023 or 2022 - it is a PIA to have a brain grow old) BCBS stopped covering brand V. CVS Caremark was and is the PBM but at that time the decision was only BCBS deciding not to cover brand V for their members. We know from others who had other insurance carriers that used CVS Caremark that they still got brand V, showing that it was not CVS Caremark dropping V at that time. After that date, I was forced to use GV and I believe (but I didn't write it down) that since then I have received different manufacturers' GV. To further to try to explain, if you notice the quote I provided above concerning BCBS using CVS Caremark, I can go to a number of different pharmacy chains to submit my script (as long as they are part of the 55,000 network pharmacies) and get GV. BUT I believe those pharmacies are mostly in charge of which GVs they carry. I am guessing they may fill their stock with more than one manufacturer of GV. I didn't mention, but although I have BCBS (whose PBM has been CVS Caremark) I have been getting my script filled at Walgreens all this time. I guess the point being that I am not sure that CVS Caremark is necessarily determining which "brand" of GV scripts are being filled with. The individual pharmacy chains I think still may control or decide whose GV to carry and to use to fill scripts. I could be wrong about this but it seems to me with all the generics out there (all drugs not just V) that if the insurance plan only covered one manufacturer, that would be a nightmare.

Thought I had more to say, but it escapes me now.

I guess I can answer that in a few months. My previous fill was Dr. Reddys but on July 10 what I got was manufactured by Strides Pharma Science Ltd, distributed by Amneal Pharmaceuticals Ltd. Funny thing, the Amneal lists Bridgewater NJ as the address. Isn’t that where Amarin’s US headquarters is?

So interested to see in 3 months whose refill I will get.

Strides says Bengaluru India.